Menu Search
Equities

AstraZeneca PLC

AZN:NSQ

AstraZeneca PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)66.01
  • Today's Change0.375 / 0.57%
  • Shares traded2.80m
  • 1 Year change+2.33%
  • Beta0.4658
Data delayed at least 15 minutes, as of Nov 25 2024 16:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AstraZeneca PLC grew revenues 3.29% from 44.35bn to 45.81bn while net income improved 81.11% from 3.29bn to 5.96bn.
Gross margin82.15%
Net profit margin12.69%
Operating margin17.97%
Return on assets6.47%
Return on equity16.67%
Return on investment8.88%
More ▼

Cash flow in USDView more

In 2023, cash reserves at AstraZeneca PLC fell by 346.00m. However, the company earned 10.35bn from its operations for a Cash Flow Margin of 22.58%. In addition the company used 4.06bn on investing activities and also paid 6.57bn in financing cash flows.
Cash flow per share3.73
Price/Cash flow per share17.54
Book value per share13.13
Tangible book value per share-6.39
More ▼

Balance sheet in USDView more

AstraZeneca PLC has a Debt to Total Capital ratio of 43.61%, a lower figure than the previous year's 61.75%.
Current ratio0.9317
Quick ratio0.7133
Total debt/total equity0.7751
Total debt/total capital0.4361
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 80.88%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)17.52
EPS (TTM) vs
TTM 1 year ago		10.05
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.